NTC and Santen partner on fixed combination ophthalmic therapeutic solution

Italian pharmaceutical company, NTC, has entered into a commercial partnership with Santen Pharmaceutical — a pharma company focused on ophthalmology.

Under the terms of the agreement, NTC has granted the licence and distribution rights of one of its research and development products — aimed at addressing unmet medical needs in the treatment of post-cataract surgery — to Santen.

The product is a new therapeutic solution, which is a fixed combination of dexamethasone with levofloxacin. This is the first product that combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops in Europe and will be supported with data from a large clinical programme involving nearly 1,000 patients.

“Partnering with a leading company in ophthalmology like Santen in EMEA, is an honour to us,” stated Riccardo Carbucicchio, President and CEO of NTC. “It also represents to NTC a confirmation about the value of its development efforts in the ophthalmic area.

Running an international research and development program is a great opportunity for an Italian based company like us, willing to invest in R&D in ophthalmology to offer to the scientific community better products with tangible novel therapeutic evidences, aimed finally to unleash improved therapeutic offering to patients.

“The ability to bring Italian innovation internationally thanks to partnership with global leading players like Santen is a great achievement for NTC,” Carbucicchio continued. The fixed combination dexamethasone + levofloxacin in eye drops aims to represent an effective therapeutic solution and at the same time to use the antibiotic therapy only for the limited time needed. NTC is engaged in a large development and clinical program on several products, meant, in particular, to reduce the antibiotic exposure to patients and to improve compliance for a better therapeutic outcome in ophthalmology.”